Back to Search Start Over

Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan.

Authors :
Feemster KA
Kim Y
Abe M
Johnson K
Sasaki S
Source :
Expert review of vaccines [Expert Rev Vaccines] 2022 May; Vol. 21 (5), pp. 589-590. Date of Electronic Publication: 2022 Feb 16.
Publication Year :
2022

Details

Language :
English
ISSN :
1744-8395
Volume :
21
Issue :
5
Database :
MEDLINE
Journal :
Expert review of vaccines
Publication Type :
Report
Accession number :
35172667
Full Text :
https://doi.org/10.1080/14760584.2022.2036127